MX2022010204A - Metodos para reducir la expresion de htt. - Google Patents
Metodos para reducir la expresion de htt.Info
- Publication number
- MX2022010204A MX2022010204A MX2022010204A MX2022010204A MX2022010204A MX 2022010204 A MX2022010204 A MX 2022010204A MX 2022010204 A MX2022010204 A MX 2022010204A MX 2022010204 A MX2022010204 A MX 2022010204A MX 2022010204 A MX2022010204 A MX 2022010204A
- Authority
- MX
- Mexico
- Prior art keywords
- reducing
- methods
- huntington
- disease
- ameliorating
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000023105 Huntington disease Diseases 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000024806 Brain atrophy Diseases 0.000 abstract 1
- 241000764238 Isis Species 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 206010056677 Nerve degeneration Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 abstract 1
- 238000012739 integrated shape imaging system Methods 0.000 abstract 1
- 230000020763 muscle atrophy Effects 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 230000009747 swallowing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062980010P | 2020-02-21 | 2020-02-21 | |
| PCT/US2021/018681 WO2021168183A1 (en) | 2020-02-21 | 2021-02-19 | Methods for reducing htt expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010204A true MX2022010204A (es) | 2022-09-19 |
Family
ID=77391689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010204A MX2022010204A (es) | 2020-02-21 | 2021-02-19 | Metodos para reducir la expresion de htt. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230108340A1 (enExample) |
| EP (1) | EP4107269A4 (enExample) |
| JP (1) | JP2023515466A (enExample) |
| KR (1) | KR20220144837A (enExample) |
| CN (1) | CN115279903A (enExample) |
| AU (1) | AU2021224729A1 (enExample) |
| BR (1) | BR112022016370A2 (enExample) |
| CA (1) | CA3172336A1 (enExample) |
| IL (1) | IL295625A (enExample) |
| MX (1) | MX2022010204A (enExample) |
| WO (1) | WO2021168183A1 (enExample) |
| ZA (1) | ZA202209112B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025265013A2 (en) | 2024-06-20 | 2025-12-26 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of huntingtin (htt), compositions thereof, and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1991677A2 (en) * | 2006-01-26 | 2008-11-19 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
| NZ714887A (en) * | 2009-09-11 | 2019-07-26 | Ionis Pharmaceuticals Inc | Modulation of huntingtin expression |
| LT3052628T (lt) * | 2013-10-04 | 2020-09-10 | Alnylam Pharmaceuticals, Inc. | Kompozicijos ir būdai alas1 geno raiškai nuslopinti |
| EP3797780B1 (en) * | 2014-04-17 | 2022-09-14 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
| IL320434A (en) * | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| US11268093B2 (en) * | 2017-01-03 | 2022-03-08 | Rula Zain-Luqman | Therapeutic method for huntington's disease |
| CN114286710A (zh) * | 2019-06-28 | 2022-04-05 | 宾州研究基金会 | 治疗亨廷顿病的方法和材料 |
-
2021
- 2021-02-19 KR KR1020227032214A patent/KR20220144837A/ko active Pending
- 2021-02-19 EP EP21757534.9A patent/EP4107269A4/en not_active Withdrawn
- 2021-02-19 CA CA3172336A patent/CA3172336A1/en active Pending
- 2021-02-19 WO PCT/US2021/018681 patent/WO2021168183A1/en not_active Ceased
- 2021-02-19 CN CN202180016151.4A patent/CN115279903A/zh active Pending
- 2021-02-19 BR BR112022016370A patent/BR112022016370A2/pt not_active Application Discontinuation
- 2021-02-19 JP JP2022549789A patent/JP2023515466A/ja active Pending
- 2021-02-19 MX MX2022010204A patent/MX2022010204A/es unknown
- 2021-02-19 US US17/800,785 patent/US20230108340A1/en active Pending
- 2021-02-19 AU AU2021224729A patent/AU2021224729A1/en active Pending
- 2021-02-19 IL IL295625A patent/IL295625A/en unknown
-
2022
- 2022-08-15 ZA ZA2022/09112A patent/ZA202209112B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021168183A1 (en) | 2021-08-26 |
| IL295625A (en) | 2022-10-01 |
| CA3172336A1 (en) | 2021-08-26 |
| BR112022016370A2 (pt) | 2022-10-04 |
| AU2021224729A1 (en) | 2022-09-08 |
| EP4107269A1 (en) | 2022-12-28 |
| JP2023515466A (ja) | 2023-04-13 |
| US20230108340A1 (en) | 2023-04-06 |
| KR20220144837A (ko) | 2022-10-27 |
| EP4107269A4 (en) | 2024-11-20 |
| CN115279903A (zh) | 2022-11-01 |
| ZA202209112B (en) | 2024-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2731000C2 (ru) | Нейроактивные стероиды, композиции и способы их применения | |
| Young et al. | Gabapentin as an adjunctive treatment in bipolar disorder | |
| ZA202209112B (en) | Methods for reducing htt expression | |
| Finkel et al. | FP. 24 RAINBOWFISH: preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA) | |
| Bonsett | Pseudohypertrophic muscular dystrophy: Distribution of degenerative features as revealed by an anatomical study | |
| MX2023008922A (es) | Compuestos y metodos para modular la huntingina. | |
| Yonekawa et al. | Extremely severe complicated spastic paraplegia 3A with neonatal onset | |
| US20140212405A1 (en) | Fibrinolytic/Proteolytic Treatment of Myofacial and Neuropathic Pain and Related Conditions | |
| Mackenzie | The action of muscles | |
| Mackenzie | The action of muscles: including muscle rest and muscle re-education | |
| Somerville et al. | Valproic acid: treatment of myoclonus in dyssynergia cerebellaris myoclonica | |
| Fotiadis et al. | Hemiplegic shoulder syndrome: Possible underlying neurophysiological mechanisms | |
| Khongprasert et al. | Thai Classical Dance: From being part of the culture to being an exercise | |
| Laios et al. | Are Drugs Always the Proper Solution to Therapeutic Dilemmas? Non-drug Approaches to the Post-traumatic Stress “Waking Corpse” Syndrome | |
| Ornsteen | The syndrome of amyotrophic lateral sclerosis in epidemic encephalitis | |
| Wang et al. | Electroacupuncture with combined Chinese herbal, Qidong Huoluo granule for Amyotrophic Lateral Sclerosis: A 9-month Case Report | |
| CN200984257Y (zh) | 分体式可调节颈托 | |
| ISLAM et al. | Management of Temporomandibular Joint Dysfunction Syndrome by Occlusal Splint Therapy and Facial Muscles Exercise-A Comparative Study | |
| Rosifini Alves Rezende | Nerve Transfer for Intrinsic Hand Dysfunction in Brown-Vialetto-Van Laere Syndrome: Expanding the Role of SETS in Motor Neuronopathies | |
| Jeong et al. | Multi Tasks Influence Postural Stability During Gait Termination: 1730 | |
| Sreeremya | Clinical Perspectives of Bowen Therapy-Review | |
| Watve et al. | Clinical profiling from speech-language pathologists' perspectives in Wallenberg syndrome: A case series. | |
| Syukkur et al. | Effect of Giving Red Ginger Oil on WOMAC Scores in Elderly People with Osteoarthritis | |
| WO2023107042A3 (en) | Therapeutic hand system | |
| Desai et al. | Neurosyphilis presenting as longitudinal extensive transverse myelitis [LETM] |